@article{WorkuStichDaugschiesetal.2015, author = {Worku, Netsanet and Stich, August and Daugschies, Arwid and Wenzel, Iris and Kurz, Randy and Thieme, Rene and Kurz, Susanne and Birkenmeier, Gerd}, title = {Ethyl Pyruvate Emerges as a Safe and Fast Acting Agent against Trypanosoma brucei by Targeting Pyruvate Kinase Activity}, series = {PLoS ONE}, volume = {10}, journal = {PLoS ONE}, number = {9}, doi = {10.1371/journal.pone.0137353}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-150002}, pages = {e0137353}, year = {2015}, abstract = {Background Human African Trypanosomiasis (HAT) also called sleeping sickness is an infectious disease in humans caused by an extracellular protozoan parasite. The disease, if left untreated, results in 100\% mortality. Currently available drugs are full of severe drawbacks and fail to escape the fast development of trypanosoma resistance. Due to similarities in cell metabolism between cancerous tumors and trypanosoma cells, some of the current registered drugs against HAT have also been tested in cancer chemotherapy. Here we demonstrate for the first time that the simple ester, ethyl pyruvate, comprises such properties. Results The current study covers the efficacy and corresponding target evaluation of ethyl pyruvate on T. brucei cell lines using a combination of biochemical techniques including cell proliferation assays, enzyme kinetics, phasecontrast microscopic video imaging and ex vivo toxicity tests. We have shown that ethyl pyruvate effectively kills trypanosomes most probably by net ATP depletion through inhibition of pyruvate kinase (Ki = 3.0\(\pm\)0.29 mM). The potential of ethyl pyruvate as a trypanocidal compound is also strengthened by its fast acting property, killing cells within three hours post exposure. This has been demonstrated using video imaging of live cells as well as concentration and time dependency experiments. Most importantly, ethyl pyruvate produces minimal side effects in human red cells and is known to easily cross the blood-brain-barrier. This makes it a promising candidate for effective treatment of the two clinical stages of sleeping sickness. Trypanosome drug-resistance tests indicate irreversible cell death and a low incidence of resistance development under experimental conditions. Conclusion Our results present ethyl pyruvate as a safe and fast acting trypanocidal compound and show that it inhibits the enzyme pyruvate kinase. Competitive inhibition of this enzyme was found to cause ATP depletion and cell death. Due to its ability to easily cross the blood-brain-barrier, ethyl pyruvate could be considered as new candidate agent to treat the hemo-lymphatic as well as neurological stages of sleeping sickness.}, language = {en} } @article{WichmannPoppertVonThienetal.2013, author = {Wichmann, Dominic and Poppert, Sven and Von Thien, Heidrun and Clerinx, Johannes and Dieckmann, Sebastian and Jensenius, Mogens and Parola, Philippe and Richter, Joachim and Schunk, Mirjam and Stich, August and Zanger, Philipp and Buchard, Gerd D. and Tannich, Egbert}, title = {Prospective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis}, series = {BMC Infectious Diseases}, volume = {13}, journal = {BMC Infectious Diseases}, number = {55}, issn = {1471-2334}, doi = {10.1186/1471-2334-13-55}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-121952}, year = {2013}, abstract = {Background: Acute schistosomiasis constitutes a rare but serious condition in individuals experiencing their first prepatent Schistosoma infection. To circumvent costly and time-consuming diagnostics, an early and rapid diagnosis is required. So far, classic diagnostic tools such as parasite microscopy or serology lack considerable sensitivity at this early stage of Schistosoma infection. To validate the use of a blood based real-time polymerase chain reaction (PCR) test for the detection of Schistosoma DNA in patients with acute schistosomiasis who acquired their infection in various endemic regions we conducted a European-wide prospective study in 11 centres specialized in travel medicine and tropical medicine. Methods: Patients with a history of recent travelling to schistosomiasis endemic regions and freshwater contacts, an episode of fever (body temperature >= 38.5 degrees C) and an absolute or relative eosinophil count of >= 700/mu l or 10\%, were eligible for participation. PCR testing with DNA extracted from serum was compared with results from serology and microscopy. Results: Of the 38 patients with acute schistosomiasis included into the study, PCR detected Schistosoma DNA in 35 patients at initial presentation (sensitivity 92\%). In contrast, sensitivity of serology (enzyme immunoassay and/or immunofluorescence assay) or parasite microscopy was only 70\% and 24\%, respectively. Conclusion: For the early diagnosis of acute schistosomiasis, real-time PCR for the detection of schistosoma DNA in serum is more sensitive than classic diagnostic tools such as serology or microscopy, irrespective of the region of infection. Generalization of the results to all Schistosoma species may be difficult as in the study presented here only eggs of S. mansoni were detected by microscopy. A minimum amount of two millilitre of serum is required for sufficient diagnostic accuracy.}, language = {en} } @article{UnnewehrStich2015, author = {Unnewehr, Markus and Stich, August}, title = {Fighting Hepatitis B in North Korea: Feasibility of a Bi-modal Prevention Strategy}, series = {Journal of Korean Medical Science}, volume = {30}, journal = {Journal of Korean Medical Science}, doi = {10.3346/jkms.2015.30.11.1584}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-138773}, pages = {1584-1588}, year = {2015}, abstract = {In North Korea, the prevalence of hepatitis B is high due to natural factors, gaps in vaccination, and the lack of antiviral treatment. Aid projects are urgently needed, however impeded by North Korea's political and economical situation and isolation. The feasibility of a joint North Korean and German humanitarian hepatitis B prevention program was assessed. Part 1: Hepatitis B vaccination catch-up campaign. Part 2: Implementation of endoscopic ligation of esophageal varices (EVL) by trainings in Germany and North Korea. By vaccinating 7 million children between 2010 and 2012, the hepatitis B vaccination gap was closed. Coverage of 99.23\% was reached. A total of 11 hepatitis B-induced liver cirrhosis patients (mean age 41.1 yr) with severe esophageal varices and previous bleedings were successfully treated by EVL without major complications. A clinical standard operating procedure, a feedback system and a follow-up plan were developed. The bi-modal preventive strategy was implemented successfully. Parts of the project can serve as an example for other low-income countries, however its general transferability is limited due to the special circumstances in North Korea.}, language = {en} } @article{GrossAmuzudeCimanetal.2011, author = {Groß, Uwe and Amuzu, Sylvarius K. and de Ciman, Ring and Kassimova, Iparkhan and Groß, Lisa and Rabsch, Wolfgang and Rosenberg, Ulrike and Schulze, Marco and Stich, August and Zimmermann, Ortrud}, title = {Bacteremia and Antimicrobial Drug Resistance over Time, Ghana}, series = {Emerging Infectious Diseases}, volume = {17}, journal = {Emerging Infectious Diseases}, number = {10}, doi = {10.3201/edi1710.110327}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-133805}, pages = {1879-1882}, year = {2011}, abstract = {Bacterial distribution and antimicrobial drug resistance were monitored in patients with bacterial bloodstream infections in rural hospitals in Ghana. In 2001-2002 and in 2009, Salmonella enterica serovar Typhi was the most prevalent pathogen. Although most S. enterica serovar Typhi isolates were chloramphenicol resistant, all isolates tested were susceptible to ciprofloxacin.}, language = {en} }